Last reviewed · How we verify
Levobupivacaine 10 mL
Levobupivacaine 10 mL is a marketed anesthetic agent developed by Pontificia Universidad Catolica de Chile, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection offered by its key patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Levobupivacaine 10 mL |
|---|---|
| Also known as | Chirocaine |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer (PHASE2)
- Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis (NA)
- Observational Retrospective Study on Spinal Analgesia in Laparoscopic and Laparotomic Hysterectomy
- Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery (PHASE2)
- Cardiac Sympathetic Denervation in Patients With Refractory Arrhythmic Storm: a Single-center Case Series
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
- Optimal Postoperative Chest Tube and Pain Management in Patients Surgically Treated for Primary Spontaneous Pneumothorax (Pneumotrial) (NA)
- Intrathecal Morphine Versus Epidural Analgesia for Open Colon Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levobupivacaine 10 mL CI brief — competitive landscape report
- Levobupivacaine 10 mL updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI